DiagnostykaFRA:7JS +1.17%19 1-Year ROIIC % is 11.01 as of Mar. 2026. GuruFocus rates FRA:7JS with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 207 Medical Diagnostics & Research companies, Diagnostyka ranks better than 58.94% on this metric.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Diagnostyka's 1-Year ROIIC % for the quarter that ended in Mar. 2026 was 11.01%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Diagnostyka's 1-Year ROIIC % or its related term are showing as below:
FRA:7JS's 1-Year ROIIC % is ranked better than 58.94% of 207
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.77
vs FRA:7JS: 11.01
Diagnostyka (FRA:7JS) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Diagnostyka 1-Year ROIIC % Related Terms
Diagnostyka 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Diagnostyka's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7JS vs TMO, DHR, IDXX: 1-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Diagnostyka's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnostyka 1-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diagnostyka's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Diagnostyka's 1-Year ROIIC % falls into.
Diagnostyka's 1-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( 75.9882 (Mar. 2026) - 65.2924 (Mar. 2025) )
/
( 500.425 (Mar. 2026) - 403.312 (Mar. 2025) )
=
10.6958
/
97.113
=
11.01%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Diagnostyka (FRA:7JS) has a 1-Year ROIIC % of 11.01 as of Mar. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Diagnostyka and its competitors. According to the industry distribution chart, Diagnostyka ranks #85 out of 207 companies in the Medical Diagnostics & Research industry, placing it in the top 41.1%.
Is Diagnostyka's 1-Year ROIIC % too high?
Diagnostyka's current 1-Year ROIIC % is 11.01. The Medical Diagnostics & Research industry median 1-Year ROIIC % is 2.77. Diagnostyka's value of 11.01 is 297.5% above this industry median. Based on the distribution chart, Diagnostyka ranks #85 out of 207 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diagnostyka has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Diagnostyka's 1-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diagnostyka ranks #85 out of 207 companies for 1-Year ROIIC %. This puts Diagnostyka in the upper half of its industry. The industry median 1-Year ROIIC % is 2.77. Diagnostyka's value of 11.01 is 297.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Medical Diagnostics & Research company?
The median 1-Year ROIIC % among Medical Diagnostics & Research companies is 2.77, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diagnostyka's current 1-Year ROIIC % of 11.01 is 297.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Diagnostyka and its competitors. For the Medical Diagnostics & Research industry, the median 1-Year ROIIC % is 2.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnostyka's current 1-Year ROIIC % is 11.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnostyka stock overvalued right now?
Diagnostyka (FRA:7JS) has a current 1-Year ROIIC % of 11.01. The current 1-Year ROIIC % is 11.01 and 297.5% above the Medical Diagnostics & Research industry median of 2.77. Diagnostyka's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Diagnostyka (FRA:7JS), the current 1-Year ROIIC % is 11.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Diagnostyka SA is engaged in providing laboratory diagnostics services in Poland. The company offers comprehensive laboratory services from collecting biological material, through testing, to providing results online.
19GF Score
Get the complete analysis for FRA:7JS
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7JS has been successfully added to your 
